Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress. The Company is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious disease, autoimmunity and cancer.

“The third quarter of 2023 was a period of solid progress for the Company. We have since revealed the evolution of the company identity from Vaccitech to Barinthus Bio. This change reflects the evolution of our pipeline beyond vaccines, towards T cell immunotherapeutic candidates designed to guide the capabilities of T cells, to stimulate their disease-fighting capacity or to restore immune balance,” said Bill Enright, Chief Executive Officer of Barinthus Bio. “We remain focused on progressing our pipeline, particularly in HBV, for which upcoming preliminary data from both of our Phase 2 trials will be presented at The American Association for the Study of Liver Diseases – The Liver Meeting® 2023 this month.”

Recent Corporate Developments

  • In November 2023, the Company announced it changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The Company’s new name takes inspiration from “Barinthus,” the mythological navigator who guided King Arthur of Britain by ship to the island of Avalon to be healed when he was wounded. The story of the legendary king being guided to a place of healing is reflective of the way the Company’s proprietary platforms and technology are designed to guide the immune system to treat infectious diseases, autoimmunity and cancer.
  • On November 6, 2023, the Company held a general meeting where its shareholders approved resolutions granting the Company’s board of directors or any duly authorized committee of the board of directors an increase in the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from pre-emption rights. Pursuant to such approval, our board of directors was authorized to allot shares up to an aggregate nominal amount of £1,928, free from statutory pre-emption rights.

Upcoming Milestones

  • In the fourth quarter of 2023, the Company expects to:
    • Announce interim efficacy data from HBV003 (NCT05343481), a Phase 2b clinical trial of VTP-300, that further evaluates its potential as a component of a functional cure for chronic Hepatitis B.
    • Announce interim efficacy data from the Phase 2a clinical trial (ACTRN12622000317796) collaboration with Arbutus of VTP-300 in combination with Arbutus’ siRNA therapeutic candidate, AB-729 for chronic hepatitis B.
    • Submit a regulatory submission application in Australia for VTP-1000, the Company’s lead SNAP-TI candidate, for the treatment of celiac disease.

Third Quarter 2023 Financial Highlights

  • Cash position: As of September 30, 2023, the Company had cash and cash equivalents of $160.3 million, compared to $173.0 million as of June 30, 2023. The net cash used in operating activities was $11.2 million, primarily resulting from its net loss of $14.1 million adjusted by unrealised foreign exchange gains of $6.2 million, depreciation and amortization of $1.5 million, and changes in its operating assets and liabilities. Based on current research and development plans, the Company expects its cash runway to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.
  • Research and development expenses: Research and development expenses were $15.1 million in the third quarter of 2023 compared to $13.5 million in the second quarter of 2023, showing increased spend due to the phasing of ongoing clinical trials. VTP-300 HBV research and development expenses increased as a result of the increased trial cost and manufacturing development costs, VTP-850 Prostate cancer has also increased as a result of the increased trial costs as the trial progresses. The quarter-on-quarter R&D expense per program is outlined in the following table.
Three months ended September 30, 2023 June 30, 2023 Change
  $ 000 $ 000 $ 000  
Direct research and development expenses by program:      
VTP-200 HPV   1,288   1,837   (549 )
VTP-300 HBV   4,877   3,757   1,120  
VTP-600 NSCLC1   155   79   76  
VTP-850 Prostate cancer   1,724   242   1,482  
VTP-1000/VTP-1100 Celiac/HPV Cancer   2,507   3,018   (511 )
Other and earlier stage programs   1,069   701   368  
Total direct research and development expenses   11,620   9,634   1,986  
Indirect research and development expenses:      
Personnel-related (including share-based compensation)   2,711   3,388   (677 )
Facility-related   368   202   166  
Other internal costs   445   319   126  
Total indirect research and development expenses   3,524   3,909   (385 )
Total research and development expense   15,144   13,543   1,601  

1 The VTP-600 NSCLC Phase 1/2a trial is sponsored by Cancer Research UK.

  • General and administrative expenses: General and administrative expenses were $1.0 million in the third quarter of 2023, compared to $13.1 million in the second quarter of 2023. The decrease was mainly attributable to the unrealized foreign exchange gain of $6.6 million in the third quarter of 2023, compared to an unrealized foreign exchange loss of $4.2 million in the second quarter of 2023. The remainder of the decrease was primarily attributable to a decrease in legal and professional fees of $0.5 million and decrease in share-based compensation expense.
  • Net loss: For the third quarter of 2023, the Company generated a net loss attributable to its shareholders of $14.1 million, or $0.37 per share on both basic and fully diluted bases, compared to a net loss attributable to shareholders of $23.8 million, or $0.62 per share on both basic and fully diluted bases in the second quarter of 2023.

About Barinthus Bio

We are a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping patients and their families is the guiding principle at the heart of Barinthus Bio. The company stands apart through its broad pipeline, built around four proprietary platform technologies; ChAdOx, MVA, SNAP-TI and SNAP-CI. Barinthus Bio is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B viral (HBV) infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. Barinthus Bio’s proven scientific expertise, high-value portfolio and focus on product development uniquely positions the company to navigate towards delivering treatments for patients with infectious diseases, autoimmunity and cancers that have a significant impact on their lives every day. For more information, visit www.barinthusbio.com.

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “would,” “aim,” “forward,” “expect,” “plan,” “intend,” “believe,” “potential,” “continue,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward looking statements include express or implied statements regarding the Company’s future expectations, plans and prospects, and include, without limitation, statements regarding the timing and advancement of the Company’s programs, including the clinical trials of VTP-200, VTP-300, and VTP-850, statements regarding the timing for the potential IND application for VTP-1000, statements regarding the presentation of interim data, including with respect to VTP-300, and statements regarding the Company’s capital, including its cash runway. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the success, cost and timing of the Company’s product development activities and planned and ongoing clinical trials, the Company’s ability to execute on its strategy, regulatory developments, approval of the Company’s product candidates, the Company’s ability to fund its operations and access capital, and global economic uncertainty, including disruptions in the banking industry, the conflict in Ukraine, and the conflict in Israel and Gaza, and other risks identified in the Company’s filings with the Securities and Exchange Commission (the SEC), including its Annual Report on Form 10-K for the year ended December 31, 2022, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

BARINTHUS BIOTHERAPEUTICS PLC

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)

(UNAUDITED)

      September 30,     December 31,        
      2023       2022          
  ASSETS                  
  Current assets:                  
  Cash and cash equivalents $ 160,309   $ 194,385      
  Accounts receivable         323          
  Accounts receivable - related parties         5,524          
  Research and development incentives receivable   4,172       4,541          
  Prepaid expenses and other current assets   6,584       8,268          
  Total current assets   171,065       213,041          
  Goodwill   12,209       12,209          
  Property and equipment, net   12,269       7,957          
  Intangible assets, net   25,898       28,269          
  Right of use assets, net   7,474       7,753          
  Other assets   1,055       976          
  Total assets $ 229,970     $ 270,205          
                     
LIABILITIES AND SHAREHOLDERS’ EQUITY                  
                     
Current liabilities:              
  Accounts payable $ 5,145   $ 3,748      
  Accrued expenses and other current liabilities   11,923       8,061          
  Operating lease liability - current   1,501       433          
  Total current liabilities   18,569       12,242          
  Non-Current liabilities:                  
  Operating lease liability   11,202       8,340          
  Contingent consideration   1,797       1,711          
  Deferred tax liability, net   1,521       3,746          
  Other non-current liabilities   1,278       965          
  Total liabilities $ 34,367     $ 27,004          
  Commitments and contingencies (Note 14)                  
  Shareholders’ equity:                  
  Ordinary shares, £0.000025 nominal value; 38,546,594 shares authorized, issued and outstanding (December 31, 2022:                  
  authorized, issued and outstanding: 37,683,531)   1       1          
  Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2022: authorized,                  
  issued and outstanding: 63,443)   86       86          
  Deferred B shares, £0.01 nominal value; nil shares authorized, issued and outstanding (December 31, 2022:authorized,                  
  issued and outstanding: 570,987)         8          
  Deferred C shares, £0.000007 nominal value, nil shares authorized, issued and outstanding (December 31, 2022:                  
  authorized, issued and outstanding: 27,828,231)         0          
  Additional paid-in capital   385,707       379,504          
  Accumulated deficit   (159,297 )     (103,243 )        
  Accumulated other comprehensive loss – foreign currency translation adjustments   (31,099 )     (33,460 )        
  Total shareholders’ equity attributable to Barinthus Biotherapeutics plc shareholders   195,398       242,896          
  Noncontrolling interest   205       305          
  Total shareholders’ equity $ 195,603   $ 243,201      
                     
  Total liabilities and shareholders’ equity $ 229,970     $ 270,205          
                     

1 indicates amount less than thousand.

BARINTHUS BIOTHERAPEUTICS PLC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)

(UNAUDITED)

                         
    Three months ended     Nine months ended
    September 30, 2023   September 30, 2022   September 30, 2023   September 30, 2022
License revenue (1)   $     $ 6,165     $ 802     $ 38,237  
Research grants and contracts                       9  
Total revenue           6,165       802       38,246  
Operating expenses                        
Research and development     15,144       9,744       38,501       30,165  
General and administrative     961       (10,815 )     26,227       (12,971 )
Total operating expenses     16,105       (1,071 )     64,728       17,194  
(Loss)/income from operations     (16,105 )     7,236       (63,926 )     21,052  
Other income (expense):                        
Interest income     196       1,024       2,306       1,776  
Interest expense     (7 )     11       (21 )     3  
Research and development incentives     1,205       (724 )     2,921       1,150  
Other income     (2 )           308       51  
Total other income (expense)     1,392       311       5,514       2,980  
(Loss)/profit before income tax     (14,713 )     7,547       (58,412 )     24,032  
Tax benefit     603       674       2,255       2,452  
Net (loss)/income     (14110 )     8,221       (56,157 )     26,484  
Net loss attributable to noncontrolling interest     38       21       103       47  
Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders     (14,072 )     8,242       (56,054 )     26,531  
                         
Weighted-average ordinary shares outstanding, basic     38,533,833       37,247,123       38,320,208       37,213,787  
Weighted-average ordinary shares outstanding, diluted     38,533,833       38,156,564       38,320,208       38,226,092  
Net (loss)/income per share attributable to ordinary shareholders, basic   $ (0.37 )   $ 0.22     $ (1.46 )   $ 0.71  
Net (loss)/income per share attributable to ordinary shareholders, diluted   $ (0.37 )   $ 0.22     $ (1.46 )   $ 0.69  
                         
Net (loss)/income   $ (14,110 )   $ 8,221     $ (56,157 )   $ 26,484  
Other comprehensive gain/(loss) – foreign currency translation adjustments     (7,820 )     (19,940 )     2,364       (42,730 )
Comprehensive loss     (21,930 )     (11,719 )     (53,793 )     (16,246 )
Comprehensive loss attributable to noncontrolling interest     48       51       100       122  
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders   $ (21,882 )   $ (11,668 )   $ (53,693 )   $ (16,124 )

1 Includes license revenue from related parties for the three and nine month periods ended September 30, 2023 of $Nil million and $0.8 million, respectively and for the three and nine month periods ended September 30, 2022 of $6.2 million and $38.2 million, respectively.

IR contacts:
Christopher M. Calabrese
Managing Director
LifeSci Advisors
+1 917-680-5608
ccalabrese@lifesciadvisors.com

Kevin Gardner
Managing Director
LifeSci Advisors
+1 617-283-2856
kgardner@lifesciadvisors.com

Media contact:
Audra Friis
Sam Brown, Inc.
+1 917-519-9577
audrafriis@sambrown.com

Company contact:
Jonothan Blackbourn
IR & PR Manager
Barinthus Bio
ir@barinthusbio.com


Primary Logo

Back to news